TMC647055
Sponsors
Tibotec Pharmaceuticals, Ireland, Janssen R&D Ireland, Merck Sharp & Dohme LLC
Conditions
Chronic Hepatitis CChronic Hepatitis C VirusHealthyHepatitis CHepatitis C, Chronic
Phase 1
TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients
CompletedNCT01202825
Start: 2010-04-30End: 2011-11-30Updated: 2013-03-04
Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
CompletedNCT01582035
Start: 2012-04-30End: 2013-11-30Updated: 2014-02-17
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
CompletedNCT01907724
Start: 2013-05-31End: 2013-08-31Updated: 2016-01-26
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants
CompletedNCT02064842
Start: 2014-02-28End: 2014-04-30Updated: 2014-05-16
Phase 2
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
CompletedNCT01724086
Start: 2012-10-31End: 2014-12-31Updated: 2016-01-11
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
CompletedNCT01852604
Start: 2013-03-31End: 2015-04-30Updated: 2015-04-23